Safety and Tolerability of NNC0141-0000-0100 in Subjects With Rheumatoid Arthritis
- Conditions
- Interventions
- First Posted Date
- 2011-06-10
- Last Posted Date
- 2014-12-23
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 92
- Registration Number
- NCT01370902
A Safety and Tolerability Extension Trial Assessing Repeated Dosing of Anti-KIR (1-7F9) Human Monoclonal Antibody in Patients With Acute Myeloid Leukaemia
- First Posted Date
- 2010-12-08
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 21
- Registration Number
- NCT01256073
- Locations
- π«π·
Hopital Dupuytren, LIMOGES Cedex, France
π«π·Institut Paoli-Calmettes, Marseille, Marseille Cedex 09, France
π«π·C.H.R.U. de Nantes - Hotel Dieu, NANTES Cedex 1, France
Study on the Anti-tumor Activity, Safety and Pharmacology of IPH2101 in Patients With Smoldering Multiple Myeloma
- First Posted Date
- 2010-10-18
- Last Posted Date
- 2014-05-09
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 30
- Registration Number
- NCT01222286
- Locations
- πΊπΈ
Sarah Cannon Research Institute, Nashville, Tennessee, United States
πΊπΈOhio State University, Columbus, Ohio, United States
πΊπΈDana-Farber Cancer Institute, Boston, Massachusetts, United States
Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse
- Conditions
- Interventions
- First Posted Date
- 2010-10-08
- Last Posted Date
- 2014-02-28
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 15
- Registration Number
- NCT01217203
- Locations
- πΊπΈ
Dana Farber, Boston, Massachusetts, United States
πΊπΈNYU Clinical Cancer Center, New York, New York, United States
πΊπΈSaint Francis Hospital, Greensville, South Carolina, United States
Evaluation of Activity, Safety and Pharmacology of IPH2101 a Human Monoclonal Antibody in Patients With Multiple Myeloma
- First Posted Date
- 2009-10-22
- Last Posted Date
- 2016-03-24
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 27
- Registration Number
- NCT00999830
- Locations
- π«π·
CHU Nancy, Nancy, France
π«π·Hopital Saint Louis, Paris, France
π«π·Institut Paoli Calmettes, Marseille, France
An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma
- Conditions
- First Posted Date
- 2007-11-01
- Last Posted Date
- 2016-03-31
- Lead Sponsor
- Innate Pharma
- Target Recruit Count
- 32
- Registration Number
- NCT00552396
- Locations
- πΊπΈ
Ohio State University Medical Center, Columbus, Ohio, United States
πΊπΈIndiana University Cancer Center, Indianapolis, Indiana, United States
πΊπΈMont Sinai Medical Center, New York City, New York, United States